Table 1.
Characteristics of 209 patients.
| Age (years), median (range) | 74 (40–90) | Radiological appearance, n (%) | |
| Male, n (%) | 158 (75.6) | Nodular type | 94 (45.0) |
| BMI (kg/m2), mean ± SD | 23.3 ± 0.3 | Infiltrative type | 115 (55.0) |
| Underlying liver disease, n (%) | AFP (ng/dl) (%) | ||
| Alcohol | 40 (19.1) | < 200 | 171 (81.8) |
| HBV | 25 (12.2) | ≧ 200 | 38 (18.2) |
| HCV | 69 (33.0) | DCP (mAU/ml), n (%) | |
| NASH/NAFLD | 41 (19.6) | < 400 | 142 (70.0) |
| PBC | 3 (1.4) | ≧ 400 | 61 (30.0) |
| Cryptogenic | 31 (14.8) | Number of tumors, n (%) | |
| Child–Pugh class, n (%) | ≤ 3 | 93 (44.5) | |
| A | 179 (85.6) | 4–6 | 89 (42.6) |
| B | 30 (14.3) | > 7 | 27 (12.9) |
| mALBI grade, n (%) | 1 (solitary large) | 44 (20.5) | |
| 1 | 93 (44.5) | Largest tumor diameter, n (%) | |
| 2a | 45 (21.5) | ≤ 3 | 98 (46.9) |
| 2b | 69 (33.0) | 3–6 | 71 (34.0) |
| 3 | 2 (1.0) | > 6 | 40 (19.1) |
| Recurrence after curative therapy, n (%) | 103 (49.3) | Up-to-7 criteria, n (%) | |
| Previous treatment, n (%) | Within | 112 (53.6) | |
| Surgical resection | 26 (25.2) | Beyond | 97 (46.4) |
| Ablation | 42 (40.8) | ||
| TACE | 32 (31.1) | ||
| SRT | 3 (2.9) | ||
BMI, body mass index; HBV, hepatitis B virus; HCV, hepatitis C virus; NASH, nonalcoholic steatohepatitis; NAFLD, nonalcoholic fatty liver disease; PBC, primary biliary cholangitis; TACE, transarterial chemoembolization; SRT, stereotactic radiotherapy; AFP, alpha-fetoprotein; DCP, des-γ-carboxy prothrombin.